Address: Scottish Enterprise Atrium Court 50 Waterloo Street Glasgow G2 6HQ,United Kingdom
Tel: 0141 228 2000
Web: http://www.scottish-enterprise.com/
Scottish Enterprise is Scotland’s development agency that works to stimulate economic growth, improve Scotland’s business infrastructures and support business in the region.
They work in partnership with universities, colleges, local authorities and other public sector bodies to maximize their contribution to the Government Economic Strategy focusing on key sectors with high-growth potential. Amongst these priority sectors are the life sciences.
In supporting the life Sciences Scotland Strategy, Scottish Enterprise is focused on building a sustainable company base across all subsectors, developing more of companies of scale; realising the significant economic benefit from areas of world-class research strengths, such as stem cells and regenerative medicine, and clinical/translational medicine; and capitalising on key opportunities for Scotland in medical technologies and pharmaceutical services.
• Stimulate economic growth
• Improve Scotland’s business infrastructures
• Support business
Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam…
See our Cookie Privacy Policy Here
